United States Copper Index Fund vs Humana Inc — how do they compare? United States Copper Index Fund trades at $40.12 (market cap $708.28M), while Humana Inc trades at $442.89 (market cap $46.49B). The key difference: Humana Inc is far larger — about 65.6× United States Copper Index Fund's market cap, and Humana Inc pays a 0.91% dividend while United States Copper Index Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Humana Inc for 53 Days on average.
| CPER | HUM | |
|---|---|---|
Market Cap | $708.28M | $46.49B |
Volume | 339,046 | 2,567,704 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $409.85 |
52-Week Low | $30.27 | $163.67 |
Typical Hold Time | 48 Days | 53 Days |
Enterprise Value | — | $53.84B |
Dividend Yield | — | 0.91% |
Signals from Pluang's Aura AI — not financial advice
CPER is trading at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish momentum in moving averages but neutral oscillators, with key support at $39 and resistance at $40. Recent news highlights strong copper demand driven by AI infrastructure needs, though copper prices have shown volatility with recent declines.
The outlook for CPER is mixed, with positive copper demand fundamentals balanced by near-term price volatility. Investment opportunities center on exposure to copper's role in AI and electrification trends, while risks include commodity price swings and potential supply chain disruptions. Wall Street sentiment appears cautiously optimistic given copper's strategic importance.
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →